Condition

ALK Positive Non-small Cell Lung Cancer

ClinicalTrials.gov condition label

Clinical trials4

Recruiting3

Common interventions5

Lead sponsors shown3

Clinical trials

4 shown

Study of NXP900 With Lorlatinib in ALK+ Lung CancerNCT07784959 · 2026-08-17

RECRUITING

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung CancerNCT07617337 · 2026-07-24

RECRUITING

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLCNCT06092086 · 2023-08-18

RECRUITING

Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLCNCT07750704 · 2026-09-01

NOT_YET_RECRUITING

Common interventions

LorlatinibDRUG3AQUA07DRUG1LoratinibDRUG1NXP900DRUG1sacituzumab tirumotecan plus lorlatinibDRUG1

Leading sponsors

Guangdong Association of Clinical Trials2Chugai Pharmaceutical1Nuvectis Pharma, Inc.1

Trial status mix

RECRUITING3

NOT_YET_RECRUITING1

Phase mix

PHASE12

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.